IQ-AI Limited

Equities

IQAI

JE00BD4H0R42

Healthcare Facilities & Services

Market Closed - London S.E. Other stock markets 11:35:18 2024-05-15 EDT			5-day change	1st Jan Change
1.53 ^GBX	-1.29%		-7.27%	-67.45%

05-10	IQ-AI subsidiary gets rare paediatric disease designation FDA	AN
05-10	IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	MT

IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024

April 29, 2024 at 10:26 am

IQ-AI Limited provided revenue guidance for the financial year 2024. The new financial year has started off well, and revenue to date is higher than the comparable period in 2023. If this trend continues, the company expects to exceed last year's revenue.

Latest news about IQ-AI Limited

IQ-AI subsidiary gets rare paediatric disease designation FDA	05-10	AN
IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	05-10	MT
EARNINGS AND TRADING: Trident Royalties swings to profit	05-02	AN
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	04-29	CI
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
IQ-AI's Broker Exercises Option to Buy Shares in Placing	02-26	MT
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	02-22	MT
IQ-AI shares sink on discounted placing fundraise	02-22	AN
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	02-09	MT
IQ-AI subsidiary asked by FDA to resubmit and modify application	02-09	AN
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program	02-02	MT
IQ-AI celebrates USD100,000 grant for subsidiary	02-02	AN
IQ-AI falls after subsidiary notes launch of treatment access scheme	01-10	AN
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment	01-10	MT
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA	12-19	MT
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate	12-19	AN
IQ-AI's Imaging Biometrics Discloses Positive Results in Early-stage Study of Potential Brain Cancer Treatment	12-05	MT
IQ-AI stock rises on positive interim results from glioblastoma trial	12-05	AN
IQ-AI Unit Seeks Pediatric Rare Disease Designation for Brain Tumor Treatment	11-08	MT
IQ-AI says Imaging Biometrics submits paediatric rare disease request	11-08	AN
IQ-AI Applies for FDA Pediatric Rare Disease Designation	11-08	CI
IQ-AI subsidiary "central" to "landmark" brain cancer study	23-10-18	AN
IQ-AI subsidiary wins orphan drug designation from US FDA	23-10-09	AN
IQ-AI's Atypical Teratoid Rhabdoid Tumor Treatment Gains US FDA Orphan Drug Designation	23-10-09	MT
IQ-AI Halts Trading on OTCQB Venture Market in US; London Shares Up 13%	23-09-19	MT

Chart IQ-AI Limited

Duration

Period

More charts

Company Profile

IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.

Sector

Healthcare Facilities & Services

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
IQ-AI LIMITED	-67.45%	4.32M
SONIC HEALTHCARE LIMITED	-16.80%	8.79B
RADNET, INC.	+64.91%	4.19B
DR. LAL PATHLABS LIMITED	-4.03%	2.48B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-42.54%	2.29B
NEOGENOMICS, INC.	-6.49%	1.97B
FLEURY S.A.	-20.18%	1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-41.24%	1.22B
METROPOLIS HEALTHCARE LIMITED	+10.26%	1.13B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+18.74%	933M

Medical & Diagnostic Laboratories